Monitor RASONQUE's revenue trajectory in Q4 2026 as early-launch dynamics (EAP transition, waiting patients) normalize. EU approval decision and subsequent country-level launches will be key catalysts. Also watch for RASolve 301 (NSCLC) initial readout in 2027.
Drugs in focus
RVMD drug pipeline →daraxonrasib
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3 (completed with positive results) / pre-NDA
- Time to market
- NDA submission pending; potential approval in 2L PDAC possibly by Q3 2026 per Truist analyst projection, though no PDUFA date is confirmed
- Next catalyst
- None dated
What to watchDaraxonrasib's Phase 3 success in 2L pancreatic cancer is already priced in after the stock surged near its 52-week high. Near-term upside hinges on formal NDA acceptance and a confirmed PDUFA date. Watch for the NDA filing announcement, which could trigger a smaller bump, but the big binary is behind us. The real long-term story is the broader pipeline (RASolute 303 in 1L PDAC, RASolve 301 in NSCLC), those future readouts are multi-year catalysts.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $177.65entry
- T+1 · 11d ago +8.24%α +7.92% · $192.28
- T+5 · 5d ago −0.73%α −4.02% · $176.35
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines reported Q3 2026 results with RASONQUE net product revenue of $197.6M from its first five weeks of commercial availability following FDA approval in August 2026. Net loss widened to $407.5M from $305.2M a year ago, driven by higher R&D and SG&A costs. The company reiterated full-year 2026 GAAP operating expense guidance of $2.1B-$2.2B.
Key Financial Metrics
Key Facts
- RASONQUE net product revenue of $197.6M for Q3 2026, reflecting ~5 weeks of commercial availability
- FDA approved RASONQUE on August 26, 2026 for metastatic pancreatic cancer
- Positive CHMP opinion recommending EU approval received in October 2026
- Net loss of $407.5M in Q3 2026 vs $305.2M in Q3 2025
- Cash, cash equivalents and marketable securities of $3.7B as of September 30, 2026
- Received $250M first mandatory debt tranche from Royalty Pharma in October 2026
- Full-year 2026 GAAP operating expense guidance reiterated at $2.1B-$2.2B
- More than 5,000 unique patients received commercial RASONQUE through September 30, 2026
Financial Impact
RASONQUE generated $197.6M in net product revenue in its first ~5 weeks; net loss was $407.5M; cash balance $3.7B plus $250M received post-quarter
Risk Factors
- Early launch revenue includes one-time EAP transition and initial stocking, not indicative of steady-state run rate
- R&D and SG&A expenses are rising rapidly with commercialization build-out
- Net loss continues to widen; reliance on capital markets or milestone-based funding
- Regulatory and reimbursement timelines in EU and Japan uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395785 |
Track record
44 reports on RVMD
7 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 17 of 18 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Viewing Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers